Short Interest in MDxHealth SA (NASDAQ:MDXH) Grows By 88.5%

MDxHealth SA (NASDAQ:MDXH) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 73,632 shares, an increase of 88.5% from the March 15th total of 39,057 shares. Based on an average trading volume of 214,324 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the shares of the stock are short sold.

MDxHealth Trading Up 6.1%

Shares of MDXH opened at $2.27 on Wednesday. The business’s 50-day moving average price is $3.06 and its 200 day moving average price is $3.58. The stock has a market capitalization of $112.37 million, a P/E ratio of -3.39 and a beta of 1.73. MDxHealth has a 1-year low of $1.51 and a 1-year high of $5.33.

MDxHealth (NASDAQ:MDXH) last released its earnings results on Friday, February 27th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The business had revenue of $29.55 million for the quarter, compared to analysts’ expectations of $26.05 million. On average, research analysts predict that MDxHealth will post -1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of MDxHealth in a research report on Tuesday, December 23rd. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Hedge Funds Weigh In On MDxHealth

Institutional investors and hedge funds have recently bought and sold shares of the business. Intesa Sanpaolo Wealth Management purchased a new position in MDxHealth during the 4th quarter valued at about $36,000. GSA Capital Partners LLP purchased a new position in MDxHealth during the 3rd quarter valued at about $48,000. Lido Advisors LLC purchased a new position in MDxHealth during the 3rd quarter valued at about $48,000. Jefferies Financial Group Inc. purchased a new position in MDxHealth during the 3rd quarter valued at about $53,000. Finally, Squarepoint Ops LLC purchased a new position in MDxHealth during the 4th quarter valued at about $51,000.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.